Oncolix Inc. (fka ONCX)

[dabullishbear]

Novartis' LFA102 is not even close to the same as Oncolix' G129R (Prolanta).

LFA102 is a monoclonal antibody, which are antibodies produced by a single clone of cells or cell line and consisting of identical antibody molecules.

G129R (Prolanta) is a prolactin receptor antagonist with a single amino acid mutation, which substitutes the 129th position on the peptide chain.

G120R (Somavert) is a human growth hormone receptor antagonist with a single amino acid mutation, which substitutes the 120th position on the peptide chain.

Human growth hormone and prolactin are both pituitary hormones of the same cytokine receptor family. They share 49 of their amino acid residues in identical positions on the peptide chain.

Can you now see how Prolanta and Somavert are more closely related than Prolanta and LFA102? The Novartis method is inferior to Prolanta which has precedent from its sibling drug known as Somavert.

Wen Chen developed both Prolanta and Somavert in the same manner. LFA102 is a completely different method of action which Wen Chen has nothing to do with. This is like comparing marijuana to opiates in terms of pain relief. Different methods of action and different drugs.

IMO